Study size categories (N=470, missing for 6*) | n (%) |
1 | 142 (30.2) |
2–9 | 133 (28.3) |
10–49 | 99 (21.1) |
50–99 | 29 (6.2) |
100–999 | 58 (12.3) |
1000–4999 | 9 (1.9) |
Paper theme (n=476) | n (%) |
Clinical features | 190 (39.9) |
Comorbidities | 38 (8.0) |
PIMS-TS | 29 (6.1) |
Neonates | 131 (27.5) |
Therapeutics | 3 (0.6) |
Epidemiology – transmission | 40 (8.4) |
Epidemiology – disease burden | 45 (9.5) |
Continent (n=476) | n (%) |
Asia | 238 (50.0) |
Europe | 141 (29.6) |
North America | 82 (17.2) |
South America | 5 (1.1) |
Australia | 4 (0.8) |
Africa | 2 (0.4) |
Multiple continents | 4 (0.8) |
*Study size missing for: three studies that included both adults and children and did not provide information about study size separately for children. Three modelling studies that either did not use any direct patient data or did not provide information about size of data source(s) from which the model(s) were extrapolated.
PIMS-TS, paediatric multisystem inflammatory syndrome – temporally associated with SARS-CoV-2.